You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(600196.SH):復宏漢霖研製的貝伐珠單抗注射液新增肝細胞癌適應症的補充申請獲受理

格隆匯8月15日丨復星醫藥(600196.SH)公佈,近日,上海復星醫藥(集團)股份有限公司控股子公司上海復宏漢霖生物技術股份有限公司及其控股子公司(合稱“復宏漢霖”)研製的貝伐珠單抗注射液(即重組抗VEGF人源化單克隆抗體注射液,商品名:漢貝泰®)新增肝細胞癌適應症的補充申請獲國家藥品監督管理局藥品審評中心受理。

截至2022年6月,集團現階段針對該藥品(包括已獲批上市適應症及複發性膠質母細胞瘤適應症,且不含對外許可中被許可方分擔的研發投入部分)的累計研發投入約為人民幣5.69億元(未經審計)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account